Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.
在 AGILE IIa 期临床试验中，对 SARS-CoV-2 基因组变异对 molnupiravir 治疗的反应进行表征
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-022-34839-9
Donovan-Banfield I'ah, Penrice-Randal Rebekah, Goldswain Hannah, Rzeszutek Aleksandra M, Pilgrim Jack, Bullock Katie, Saunders Geoffrey, Northey Josh, Dong Xiaofeng, Ryan Yan, Reynolds Helen, Tetlow Michelle, Walker Lauren E, FitzGerald Richard, Hale Colin, Lyon Rebecca, Woods Christie, Ahmad Shazaad, Hadjiyiannakis Dennis, Periselneris Jimstan, Knox Emma, Middleton Calley, Lavelle-Langham Lara, Shaw Victoria, Greenhalf William, Edwards Thomas, Lalloo David G, Edwards Christopher J, Darby Alistair C, Carroll Miles W, Griffiths Gareth, Khoo Saye H, Hiscox Julian A, Fletcher Thomas
